🟢 Senti Biosciences is trading 5% up today on FDA RMAT designation optimism and high retail sentiment

Senti Biosciences is trading 5% up at $1.05, bouncing back after a volatile week of trading around the $1.00 level.

• Investors remain optimistic following the recent FDA RMAT designation for the company's SENTI-202 cancer therapy.
• Retail sentiment is currently extremely bullish with extremely high message volume across social platforms.
• The move appears to be company-specific and sentiment-driven as broader market indices remain mixed in pre-market trading.